Fibrino 500mg Tablet 6pcs

Uses of Fibrino 500mg Tablet

Hemorrhage, Hereditary angioedema

How does Fibrino 500mg Tablet work?

Tranexamic acid is an antifibrinolytic agent that competitively inhibits the breakdown of fibrin clots.

Side Effects of Fibrino 500mg Tablet

Common side effects include headache, nasal and sinus symptoms, back pain, abdominal pain, and musculoskeletal pain. Less common side effects include arthralgia, muscle cramps and spasms, migraine, anemia, and fatigue. Visual abnormalities, hypotension (with rapid injection), nausea, vomiting, and diarrhea may occur.

Quick Suggestions:

• Fibrino 500mg Tablet helps prevent or reduce heavy bleeding post-surgery and in conditions such as heavy periods, dysfunctional uterine bleeding, and nosebleeds.
• Your doctor will prescribe the lowest effective dose for the shortest possible time necessary to relieve your symptoms.
• If taking it for heavy periods, take it on the first day, as taking it before or after will not have any benefit.
• Your doctor may monitor your vision regularly while you are taking this medicine.
• Inform your doctor if you have a history of kidney or liver disease.
• Inform your doctor if there is no improvement in your bleeding after using this medicine for three consecutive periods.

Indication of Fibrino 500mg Tablet

Medical Uses:

1. Hemoptysis (coughing up blood): Prophylaxis and therapy for cases of hemoptysis.
2. Digestive Hemorrhages: Prevention and treatment of bleeding in the digestive system.
3. Hemorrhagic Syndromes: Used in cases of hemorrhagic syndromes associated with conditions such as leukemia, cirrhosis, and hemophilia.
4. Thrombocytopenic Purpura: Treatment in cases of thrombocytopenic purpura, a condition characterized by a low platelet count.
5. Accidents during Thrombolytic Therapy and Transfusion: Used in managing bleeding complications that may occur during thrombolytic therapy and blood transfusions.

Surgical Uses:

1. Prophylaxis and Antihemorrhagic Therapy during Operations: Employed as a preventive measure and for controlling bleeding during various types of surgeries, including pulmonary, cardiovascular, abdominal, and other surgical procedures.
2. Post-operative and Traumatic Shock: Used to manage hemorrhagic complications after surgery and traumatic incidents.

Urological Uses:

1. Prophylaxis and Antihemorrhagic Therapy of Prostatic, Vesical, and Renal Surgery: Utilized in preventing and treating bleeding in urological surgeries, including those involving the prostate, bladder, and kidneys.
2. Hematurias: Used in the management of conditions characterized by the presence of blood in the urine (hematuria).

Obstetric Uses:

1. Prophylaxis and Therapy of Post-partum and Puerperium Hemorrhages: Used to prevent and treat bleeding following childbirth.
2. Hemorrhagic Metropathies: Employed in the management of abnormal bleeding disorders in the uterus.
3. Functional Menometrorrhagias: Used in cases of abnormal and heavy menstrual bleeding.
4. Idiopathic or IUD-induced Menorrhagias: Used for the treatment of idiopathic (unknown cause) or intrauterine device-induced heavy menstrual bleeding.
5. Primitive Hyperfibrinolysis: Used in conditions involving excessive fibrinolysis, such as abruptio placentae (premature placental detachment) during pregnancy.

Otorhinolaryngological Uses:

1. Prophylaxis and Antihemorrhagic Therapy during Tonsillectomy: Used to prevent and treat bleeding during tonsillectomy.
2. Specialist Surgery Generally, Epistaxis: Employed in various specialist surgeries, and for controlling nosebleeds (epistaxis).

Stomatological Uses:

1. Prophylaxis and Antihemorrhagic Therapy during Maxillofacial Operations, Tooth Extractions: Used to prevent and treat bleeding during Maxillofacial surgeries and tooth extractions.

Oncological Uses (Supportive Therapy):

1. Formation of Fibrin Capsule: Used to promote the formation of a fibrin capsule, inhibiting the growth of ovarian tumors.
2. Regression of Ascites: Employed for causing regression of ascites (accumulation of fluid in the abdominal cavity) secondary to carcinoma.
3. Reducing Bleeding during Surgical Interventions: Used to reduce bleeding during various surgical interventions in oncology.

Pharmacology

Tranexamic acid operates through competitive inhibition of the activation of plasminogen. Plasminogen is activated to plasmin, an enzyme responsible for breaking down fibrin clots, fibrinogen, and other plasma proteins. The inhibition occurs through binding to the kringle domain of plasminogen.

The primary actions include:

1. Inhibition of Plasmin Formation: Tranexamic acid reduces the conversion of plasminogen to plasmin, hindering the formation of this fibrinolytic enzyme.
2. Direct Inhibition of Plasmin Activity: Tranexamic acid also directly inhibits the activity of plasmin, although higher doses are necessary for this effect compared to the reduction in plasmin formation.

By interfering with the fibrinolytic process, tranexamic acid helps maintain hemostasis by preventing excessive breakdown of blood clots and fibrin components.

Pharmacokinetics:

• Absorption: Tranexamic acid is rapidly absorbed from the gastrointestinal tract.
• Peak Serum Levels: Maximum serum levels are achieved within 2-3 hours after administration.
• Excretion (Oral Administration): Approximately 40% of the administered dose is excreted in the urine during the first 24 hours.
• Excretion (Intravenous Administration): Following intravenous administration, 45% of the dose is excreted in the urine during the first day.

Dosage & Administration of Fibrino 500mg Tablet

• Adult Dose: Oral: Short-term management of haemorrhage: 1-1.5 g or 15-25 mg/kg bid or tid. Management of hereditary angioedema: 1-1.5 g bid or tid. Intravenous: Short-term management of haemorrhage: 0.5-1 g or 10 mg/kg tid or 25-50 mg/kg daily by continuous infusion.
• Child Dose: Oral: Short-term management of haemorrhage: 25 mg/kg bid or tid. Management of hereditary angioedema: 25 mg/kg bid or tid. Intravenous: Short-term management of haemorrhage: 10 mg/kg bid or tid.
• Renal Dose: Adjust the dose based on serum creatinine concentration.

Administration: May be taken with or without food.

Interaction

Potentially fatal interactions with estrogens, Factor IX complex concentrates, or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocytic leukemia.

Contraindications

Severe renal failure, active intravascular clotting, thromboembolic disease, color vision disorders, subarachnoid bleeding.

Pregnancy & Lactation

Tranexamic acid crosses the placenta. Clinical experience of use in pregnant women is limited. Animal studies have not supplied any evidence of an increased incidence of fetal damage. Tranexamic acid is excreted into breast milk, but it is not likely to influence the child at therapeutic doses.

Precautions & Warnings

Mild to moderate renal impairment, irregular menstrual bleeding, previous history of thromboembolic disease, and haematuria. Monitor closely in disseminated intravascular coagulation. Monitor LFT and eye examination regularly during long-term use. Discontinue if the disturbance in color vision occurs. Avoid IV in rate >1 ml/minute due to the risk of hypotension. Pregnancy, lactation.

Storage Conditions

Store in a dry place at 15-30°C, away from light and keep out of children's reach.